|
PARP9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62436730732907E-12 |
| Normal-vs-Stage2 |
3.036000E-04 |
| Normal-vs-Stage3 |
2.66231481305113E-13 |
| Normal-vs-Stage4 |
9.9124997099409E-10 |
| Stage1-vs-Stage2 |
7.179000E-03 |
| Stage1-vs-Stage3 |
5.568800E-01 |
| Stage1-vs-Stage4 |
2.954400E-01 |
| Stage2-vs-Stage3 |
5.104400E-02 |
| Stage2-vs-Stage4 |
8.040200E-03 |
| Stage3-vs-Stage4 |
2.091800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.69386999999688E-05 |
| Normal-vs-Asian |
1.0387024573788E-11 |
| Caucasian-vs-AfricanAmerican |
8.653800E-01 |
| Caucasian-vs-Asian |
2.433000E-01 |
| AfricanAmerican-vs-Asian |
5.274400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.63469238145808E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
3.781400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
3.26579996379195E-09 |
| Normal-vs-Age(81-100Yrs) |
5.081200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.033700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.409800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.822300E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.850400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.109400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.267600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.124000E-01 |
| Classical-VS-Follicular |
1.62447832963153E-12 |
| Classical-VS-Other |
5.405500E-02 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
8.08849986988491E-10 |
| Tall-VS-Other |
1.469560E-02 |
| Tall-VS-Normal |
1.76500036808136E-10 |
| Follicular-VS-Other |
5.131200E-01 |
| Follicular-VS-Normal |
7.675600E-03 |
| Other-VS-Normal |
1.505600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.77475828372553E-15 |
| Normal-vs-N1 |
8.73159988756811E-10 |
| N0-vs-N1 |
6.637900E-02 |
|
|
